Opdivo pads lead over Keytruda in 3Q15

Bristol-Myers Squibb Co. (NYSE:BMY) reported $305 million in 3Q15 sales of Opdivo nivolumab, widening its lead over rival PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK). Opdivo sales were up 150% from $122 million in 2Q15.

Also on Tuesday, Merck reported $159 million in 3Q15 sales of Keytruda, up 45% from $110 million in 2Q15. Opdivo had lagged Keytruda during its first full quarter on the market in 1Q15 (see BioCentury Extra, April 28). ...